Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This intervention refers to a multimodal analgesic approach combining general anesthesia with regional nerve blocks—specifically the Pericapsular Nerve Group (PENG) block and the Lumbar Erector Spinae Plane (ESP) block—using bupivacaine. Developed and evaluated by Tanta University, this combination is primarily indicated for postoperative pain management in geriatric patients undergoing total hip arthroplasty (THA). Bupivacaine is a long-acting local anesthetic that functions as a sodium channel blocker, preventing the generation and conduction of nerve impulses to provide localized analgesia. The PENG block targets the articular branches of the femoral, obturator, and accessory obturator nerves to provide hip-specific pain relief, while the ESP block offers broader truncal analgesia. This combination aims to reduce postoperative opioid consumption and facilitate early mobilization in elderly surgical populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on general anesthesia + bupivacaine.